Simcere Pharmaceutical Group Limited reported that it cancelled 27.50 million shares on 8 June 2026, representing 1.06% of the 2.60 billion shares outstanding at the end of May. Following the cancellation, the company’s issued share capital (excluding treasury shares) fell to 2.57 billion shares as of 30 June 2026.

The cancelled shares had been repurchased in the market between 12 January and 22 May 2026 under the board-approved buy-back mandate dated 13 June 2025. No new shares were issued and no treasury shares were transferred during the month.

Public float remained above the initial prescribed threshold of 15.45%, and the company confirmed full compliance with Hong Kong Stock Exchange requirements.

Simcere retains capacity to issue up to 235.20 million new shares under its amended Restricted Share Unit Scheme approved on 15 June 2023; however, no shares were granted or vested from this scheme in June.

There are no outstanding share options, warrants or convertible securities on the register, and the company does not maintain an authorised share-capital limit under Hong Kong’s no-par value regime.